Effect of naturally-occurring gp41 HR1 variations on susceptibility of HIV-1 to fusion inhibitors

AIDS

Volumn 19, Issue 13, 2005, Pages 1401-1405

  Chinnadurai, Raghavan ^a   Münch, Jan ^a   Kirchhoff, Frank ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Entry inhibitors; HIV 1; Resistance; T 1249; T 20

Indexed keywords

ENFUVIRTIDE; GLYCOPROTEIN GP 41; PROTEIN HR1; T 1249; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG INHIBITION; GENETIC TRANSFECTION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; VIRUS CLASSIFICATION; VIRUS ISOLATION; VIRUS MUTANT;

EID: 27544461723     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000180785.25800.de     Document Type: Article

References (28)

1. LaBranche CC, Galasso G, Moore JP, Bolognesi DP, Hirsch MS, Hammer SM. HIV fusion and its inhibition. Antiviral Res 2001; 50:95-115.
2. Moore JP, Doms RW. The entry of entry inhibitors: a fusion of science and medicine. Proc Natl Acad Sci USA 2003; 100:10598-10602.
3. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-2185.
4. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186-2195.
5. Wild C, Greenwell T, Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses 1993; 9:1051-1053.
6. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 1994; 91:9770-9774.
7. Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997; 89:263-273.
8. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997; 387:426-430.
9. Rimsky LT, Shugars DC, Matthews TJ. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 1998; 72:986-993.
10. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM. Emergence of resistant HIV-1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46:1896-1905.
11. Sista PR, Melby T, Davison D, Jin L, Mosier S, Mink M, et al. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 2004; 18:1787-1794.
12. Greenberg ML, Davison D, Jin L. In vitro antiviral activity of T-1249, a second generation fusion inhibitor. Antivir Ther 2002; 7 (Suppl 1):S10.
13. Eron JJ, Gulick RM, Bartlett JA, Merigan T, Arduino R, Kilby JM, et al. Short-term safety and antiviral activity of T-1249, a second generation fusion inhibitor. J Infect Dis 2004; 189:1075-1083.
14. Chan DC, Chutkowski CT, Kim PS. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci USA 1998; 95:15613-15617.
15. Lalezari JP, Bellos NC, Sathasivam K, Richmond GJ, Cohen CJ, Myers RA Jr, et al. T-1249 Retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen. J Infect Dis 2005; 191:1155-1163.
16. Zollner B, Feucht HH, Schroter M, Schafer P, Plettenberg A, Stoehr A, et al. Primary genotypic resistance of HIV-1 to the fusion inhibitor T-20 in long-term infected patients. AIDS 2001; 15:935-936.
17. Hanna SL, Yang C, Owen SM, Lal RB. Variability of critical epitopes within HIV-1 heptad repeat domains for selected entry inhibitors in HIV-infected populations worldwide. AIDS 2002; 16:1603-1608.
18. Xu L, Hue S, Taylor S, Ratcliffe D, Workman JA, Jackson S, et al. Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naive and -experienced patients. AIDS 2002; 16:1684-1686.
19. Roman F, Gonzalez D, Lambert C, Deroo S, Fischer A, Baurith T, et al. Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains. J Acquir Immune Defic Syndr 2003; 33:134-139.
20. Villahermosa ML, Perez-Alvarez L, Carmona R, Cuevas MT, Thomson MM, Medrano L, et al. Primary resistance mutations to fusion inhibitors and polymorphisms in gp41 sequences of HIV-1 non-B subtypes and recombinants. AIDS 2003; 17:1083-1086.
21. Munch J, Standker L, Pohlmann S, Baribaud F, Papkalla A, Rosorius O, et al. Hemofiltrate CC chemokine 1[9-74] causes effective internalization of CCR5 and is a potent inhibitor of R5-tropic human immunodeficiency virus type 1 strains in primary T cells and macrophages. Antimicrob Agents Chemother 2002; 46:982-990.
22. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, Ratner L, et al. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 2000; 74:8358-8367.
23. Armand-Ugon M, Gutierrez A, Clotet B, Este JA. HIV-1 resistance to the gp41-dependent fusion inhibitor C-34. Antiviral Res 2003; 59:137-142.
24. Perrin L, Telenti A. HIV treatment failure: testing for HIV resistance in clinical practice. Science 1998; 80:1871-1873.
25. Menzo S, Castagna A, Monachetti A, Hasson H, Danise A, Carini E, et al. Genotype and phenotype patterns of HIV-1 resistance to enfuvirtide during long-term treatment. Antimicrob Agents Chemother 2004; 48:3253-3259.
26. Heil ML, Decker JM, Sfakianos JN, Shaw GM, Hunter E, Derdeyn CA. Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site. J Virol 2004; 78:7582-7589.
27. Cilliers T, Patience T, Pillay C, Papathanasopoulos M, Morris L. Sensitivity of HIV type 1 subtype C isolates to the entry inhibitor T-20. AIDS Res Hum Retroviruses 2004; 20:477-482.
28. Papkalla A, Munch J, Otto C, Kirchhoff F. Nef enhances human immunodeficiency virus type 1 infectivity and replication independently of viral coreceptor tropism. J Virol 2002; 76:8455-8459.